EPO Upholds Revocation of 'Important' Affy Patent in Europe, Despite Appeal

According to an attorney familiar with the case, the EPO's decision could have ramifications for the "entire scientific community in Europe" and lead to potential losses in licensing fees for Affy.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.